Canada markets open in 2 hours 54 minutes

Poxel S.A. (PXXLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.60000.0000 (0.00%)
At close: 10:40AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.6000
Open2.6000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.6000 - 2.6000
52 Week Range2.1000 - 6.7000
Volume1,000
Avg. Volume0
Market Cap76.635M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-0.8710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022

    LYON, France, November 08, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2022.

  • Business Wire

    Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

    LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) were presented during the late-breaking session at The Liver Meeting® 2022, hosted by the American Association for the Study

  • Business Wire

    Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference

    LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.